Bionomics announced on 9 July 2018 that it had completed treatment in its 193-patient Phase II clinical study of BNC210 for post-traumatic stress disorder (PTSD). The RESTORE clinical study completed the treatment phase on time and the company stated that it intends to provide topline data by the end of calendar Q318.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bionomics - RESTORE trial completed, data this quarter
- Published:
18 Jul 2018 -
Author:
Dr Nathaniel Calloway -
Pages:
5
Bionomics announced on 9 July 2018 that it had completed treatment in its 193-patient Phase II clinical study of BNC210 for post-traumatic stress disorder (PTSD). The RESTORE clinical study completed the treatment phase on time and the company stated that it intends to provide topline data by the end of calendar Q318.